Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2018 02:00 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events

Annualized bleeding rate (ABR) for all 15 participants was reduced by 98 percent, while annualized infusion rate (AIR) was reduced by 99 percent as of the May 7, 2018 data cutoff Range of...
May 08, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

PHILADELPHIA, May 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
May 01, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights

PHILADELPHIA, May 01, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
April 30, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Sells Priority Review Voucher for $110 Million

PHILADELPHIA, April 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
February 23, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in March

PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
February 20, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress

PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
February 13, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

PHILADELPHIA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
February 05, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in February

PHILADELPHIA, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
January 24, 2018 16:00 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial...
January 04, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors

PHILADELPHIA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...